

## **Product** Data Sheet

# Methyclothiazide

Cat. No.: HY-B0562 CAS No.: 135-07-9

Molecular Formula:  $C_9H_{11}Cl_2N_3O_4S_2$ 

Molecular Weight: 360.24

Target: Carbonic Anhydrase

Pathway: Metabolic Enzyme/Protease

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

### **SOLVENT & SOLUBILITY**

In Vitro DMSO: 72 mg/mL (199.87 mM; Need ultrasonic and warming)

H<sub>2</sub>O: < 0.1 mg/mL (insoluble)

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|-------------------------------|-----------|------------|------------|
|                              | 1 mM                          | 2.7759 mL | 13.8796 mL | 27.7593 mL |
|                              | 5 mM                          | 0.5552 mL | 2.7759 mL  | 5.5519 mL  |
|                              | 10 mM                         | 0.2776 mL | 1.3880 mL  | 2.7759 mL  |

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

**Description**Methyclothiazide is an orally active antihypertensive agent and a diuretic agent. Methyclothiazide leads to a reduction of the vascular response to the action of endogenous vasoconstricting stimuli, such as Norepinephrine (HY-

13715). Methyclothiazide is against voltage-dependent Ca-channel (VDCC) activity in vitro  $^{[1][2][3]}$ .

IC50: voltage-dependent Ca-channel (VDCC)

by N-nitro-L-arginine (NOLA) but not indomethacin<sup>[1]</sup>.

In Vitro Methyclothiazide (0-100 μM) induces endothelium-dependent inhibition of the vasoconstrictor responses to NE and AVP only in aortas from SHR, and the maximal vasoconstrictive effect of Norepinephrine (HY-13715) and arginine vasopressin (AVP) is decreased by 59% and 32.3 %, respectively<sup>[1]</sup>.

 $Methyclothiazide~(0-100~\mu\text{M})~induces~inhibitory~effect~on~the~contractile~response~to~Norepinephrine~(HY-13715)~is~abolished~inhibitory~effect~on~the~contractile~response~to~Norepinephrine~(HY-13715)~is~abolished~inhibitory~effect~on~the~contractile~response~to~Norepinephrine~(HY-13715)~is~abolished~inhibitory~effect~on~the~contractile~response~to~Norepinephrine~(HY-13715)~is~abolished~inhibitory~effect~on~the~contractile~response~to~Norepinephrine~(HY-13715)~is~abolished~inhibitory~effect~on~the~contractile~response~to~Norepinephrine~(HY-13715)~is~abolished~inhibitory~effect~on~the~contractile~response~to~Norepinephrine~(HY-13715)~is~abolished~inhibitory~effect~on~the~contractile~response~to~Norepinephrine~(HY-13715)~is~abolished~inhibitory~effect~on~the~contractile~inhibi$ 

Methyclothiazide (100  $\mu$ M) affects the vascular responses to extracellular Ca<sup>2+</sup> under high-K<sup>+</sup> depolarizing conditions. It can reduce Ca<sup>2+</sup> contracture in a high-K<sup>+</sup>, Ca<sup>2+</sup>-free solution. The maximal contracture is reduced by 90.4%<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Colas, B., et al., Mechanisms of methyclothiazide-induced inhibition of contractile responses in rat aorta. Eur J Pharmacol, 2000. 408(1): p. 63-7.

[2]. Colas, B., et al., Direct vascular actions of methyclothiazide and indapamide in aorta of spontaneously hypertensive rats. Fundam Clin Pharmacol, 2000. 14(4): p. 363-8.

[3]. Sasaki, S. and R.D. Bunag, Methyclothiazide attenuates salt-induced hypertension without affecting sympathetic responsiveness in Dahl rats. J Cardiovasc Pharmacol, 1983. 5(3): p. 378-83.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com